1. Clinical & Scientific Overview
Ferrous Fumarate (TIP-MED-000382, Reference Code [10.7]-C112) is classified under
Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10) as a Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haemoglobin, Myoglobin & Cytochrome Synthesis).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Co-indexed constituent under primary monograph [10.7] (Oral Iron Salts (Ferrous Sulphate, Ferrous Ascorbate & Ferrous Fumarate)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.7], p. 130): • Ferrous Ascorbate (100 mg elemental Fe + Folic Acid 1.5 mg): Orofer-XT (Emcure), Livogen-XT (P&G), Ferium-XT, Autrin-XT. • Ferrous Fumarate (~33% elemental Fe): Livogen, Autrin (Pfizer), Hemsi. • Ferrous Sulphate (20% elemental Fe): Fefol (GSK—150 mg dried FeSO4 = 47 mg elemental Fe + Folic acid 0.5 mg), CGHS/Jan Aushadhi IFA tablets. • Parenteral IV Iron: Orofer-FCM / Encicarb (Ferric Carboxymaltose 500 mg/10 mL, 1000 mg/20 mL), Iron Sucrose (Orofer-S 100 mg/5 mL) — Strengths & Dosage Forms: Oral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drops; IV Injection: Iron Sucrose 20 mg/mL (5 mL), Ferric Carboxymaltose 50 mg/mL (10 mL, 20 mL)
Oral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drops; IV Injection: Iron Sucrose 20 mg/mL (5 mL), Ferric Carboxymaltose 50 mg/mL (10 mL, 20 mL)
3. Mechanism of Action & Pharmacodynamics
Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haemoglobin, Myoglobin & Cytochrome Synthesis) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10): clinical efficacy is mediated via Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haemoglobin, Myoglobin & Cytochrome Synthesis) for Prevention and treatment of Iron Deficiency Anaemia (IDA—microcytic hypochromic anaemia) in pregnancy/lactation, menorrhagia, nutritional deficiency, chronic GI blood loss (hookworm, peptic ulcer, haemorrhoids), and Chronic Kidney Disease (on erythropoietin therapy)..
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention and treatment of Iron Deficiency Anaemia (IDA—microcytic hypochromic anaemia) in pregnancy/lactation, menorrhagia, nutritional deficiency, chronic GI blood loss (hookworm, peptic ulcer, haemorrhoids), and Chronic Kidney Disease (on erythropoietin therapy)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Therapeutic IDA (Modern Hepcidin-Aware Regimen): 60 mg to 100 mg Elemental Iron ONCE DAILY or ON ALTERNATE DAYS (Recent clinical haematology studies prove that taking 60–100 mg elemental iron once daily or on alternate mornings achieves higher fractional absorption and 50% fewer GI side effects than old TDS dosing, because a single iron dose triggers a 24-hour hepatic hepcidin surge that blocks subsequent doses taken the same day!). Prophylaxis: 60 mg elemental iron + 500 mcg folic acid OD. Follow physician prescription.
Administration & Meal Timing: Best absorbed on an EMPTY STOMACH (1 hour before or 2 hours after meals) with plain water or Vitamin C / Nimbu Pani (lemon water)! However, if epigastric pain or nausea occurs, take immediately after a meal (avoiding milk, tea, coffee, or calcium at that meal!). | Mid-morning (e.g., 10:30–11:00 AM, 2 hours after breakfast and 2 hours before lunch) or before dinner—safely separated from 6 AM Levothyroxine and 2 PM Calcium!
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [10.7].
Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.
Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.
Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in Anaemia NOT caused by iron deficiency (such as Beta-Thalassaemia Trait/Major, sideroblastic anaemia, or haemolytic anaemia—giving iron in thalassaemia trait causes dangerous hepatic/cardiac iron overload!), haemochromatosis, and active peptic ulcer. Keep strictly out of reach of young children (accidental paediatric ingestion of >20–60 mg/kg elemental iron causes fatal haemorrhagic gastroenteritis and shock!).
Key Clinical Precautions: Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.
8. Adverse Effects Profile
- Harmless black or dark-green tarry discolouration of stools (unabsorbed iron reacts with colonic sulphides), epigastric cramping, nausea, metallic taste, constipation (or occasional diarrhoea). (Ferrous Ascorbate [Orofer-XT] has higher stability and better GI tolerance than raw Ferrous Sulphate).
- Oral: Corrosive gastritis/oesophageal stricture if tablet lodges in gullet; acute iron poisoning in children. Parenteral IV Iron (Iron Sucrose / Ferric Carboxymaltose): Anaphylaxis / hypersensitivity reactions, symptomatic Hypophosphataemia and osteomalacia (specifically with repeated Ferric Carboxymaltose [FCM] infusions via FGF-23 surge!), paravenous extravasation causing permanent brown skin tattooing ('iron staining').
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Drugs Impaired by Iron Chelation (Space by ≥2–4 Hours!): Levothyroxine (space ≥4 hours!), Fluoroquinolones (ciprofloxacin, levofloxacin), Tetracyclines (doxycycline), Levodopa/Carbidopa, Methyldopa, Mycophenolate, and Bisphosphonates! 2
- Drugs/Foods that Block Iron Absorption: Calcium Carbonate/Citrate, Magnesium/Aluminium Antacids, Proton Pump Inhibitors (pantoprazole—gastric acid is needed to keep Fe2+ reduced, though Ferrous Ascorbate partially overcomes this!), and Tea/Coffee! 3
- Enhancer: Vitamin C (Ascorbic Acid) keeps iron in the soluble ferrous (Fe2+) state and increases absorption by 30%
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [10.7].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Reassure about Black Stools: Warn every patient: 'Iron tablets will turn your stool black or dark green—this is completely normal and harmless!' (However, in elderly patients also taking Aspirin, Clopidogrel, or Warfarin, distinguish harmless dull green-black iron stools from shiny, foul-smelling, sticky tar-like melaena caused by stomach bleeding!). 2. Liquid Iron Tooth Staining: Dilute paediatric/adult iron syrups in water or juice and sip through a straw (or rinse mouth after) to prevent temporary dark staining of dental enamel. 3. Never combine Iron and Calcium in the same meal slot!
- Meal & Clock Timing Instruction: Best absorbed on an EMPTY STOMACH (1 hour before or 2 hours after meals) with plain water or Vitamin C / Nimbu Pani (lemon water)! However, if epigastric pain or nausea occurs, take immediately after a meal (avoiding milk, tea, coffee, or calcium at that meal!). (Mid-morning (e.g., 10:30–11:00 AM, 2 hours after breakfast and 2 hours before lunch) or before dinner—safely separated from 6 AM Levothyroxine and 2 PM Calcium!)
- Missed Dose Protocol: Take as soon as remembered (away from calcium/tea); never double the dose.
- Geriatric Dispensing Pearl: In an elderly male or postmenopausal female CGHS patient presenting with newly diagnosed Iron Deficiency Anaemia, iron is a symptom, NOT a final diagnosis—occult gastrointestinal blood loss (from Aspirin/NSAIDs, peptic ulcer, angiodysplasia, or colorectal carcinoma) must always be investigated by the physician while iron stores are replenished! Use once-daily or alternate-day dosing to prevent severe geriatric constipation.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drops; IV Injection: Iron Sucrose 20 mg/mL (5 mL), Ferric Carboxymaltose 50 mg/mL (10 mL, 20 mL)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.8]-C113 L-Methylfolate — Water-Soluble Haematinic & One-Carbon Methyl-Donor Vitamin (Essen
- [10.15]-C120 Iron Sucrose (Parenteral IV Iron) — Colloidal Macromolecular Carbohydrate-Shell Intravenous Iron Comp
- [10.15]-CMP121 Erythropoietin Alfa (rHuEPO) & Darbepoetin Alfa — Colloidal Macromolecular Carbohydrate-Shell Intravenous Iron Comp
- [10.7] Oral Iron Salts (Ferrous Sulphate, Ferrous Ascorbate & Ferrous Fumarate) — Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Min